Cardiovascular disease (CVD) has remained the leading cause of death among adults for more than one hundred years. With persistently suboptimal outcomes and a profound economic burden on our healthcare system, there is growing interest in alternative treatment approaches for CVD. One such approach is Tongxinluo (TXL) capsules, a Traditional Chinese Medicine (TCM). TXL is commonly used in China and offers a potentially safe, efficacious, and cost-effective treatment option. To address the limited awareness of TXL in the United States, this narrative review will provide a broad overview of its composition, pharmacological mechanisms, and clinical applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/CRD.0000000000000892 | DOI Listing |
J Mol Histol
March 2025
Graduate School, Hebei Medical University, Shijiazhuang, Hebei, 050017, China.
Acute myocardial infarction (AMI) is a leading cause of heart failure, often accompanied by myocardial fibrosis (MF), characterized by excessive extracellular matrix accumulation. Endothelial-to-mesenchymal transition (EndMT) plays a key role in MF progression post-AMI. Neuregulin-1 (NRG-1), a growth factor with cardioprotective properties, has emerged as a potential therapeutic target.
View Article and Find Full Text PDFCardiol Rev
March 2025
From the Department of Medicine, Westchester Medical Center, Valhalla, NY.
Cardiovascular disease (CVD) has remained the leading cause of death among adults for more than one hundred years. With persistently suboptimal outcomes and a profound economic burden on our healthcare system, there is growing interest in alternative treatment approaches for CVD. One such approach is Tongxinluo (TXL) capsules, a Traditional Chinese Medicine (TCM).
View Article and Find Full Text PDFPhytomedicine
September 2024
Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, Shaanxi University of Chinese Medicine, Xi'an 712046, Shaanxi, PR China; School of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an 712046, Shaanxi, PR China. Electronic address:
Background: Cardiovascular and cerebrovascular disease (CCVD) is the leading cause of morbidity and mortality worldwide, imposing a significant economic burden on individuals and societies. For the past few years, Traditional Chinese Medicine (TCM) has attracted much attention due to its advantages such as fewer side effects in the treatment of CCVD. TXL has shown great promise in the treatment of CCVD.
View Article and Find Full Text PDFChin J Integr Med
July 2024
Graduate School, Hebei University of Chinese Medicine, Shijiazhuang, 050090, China.
Objective: To investigate the potential role of Tongxinluo (TXL) in attenuating myocardial fibrosis after myocardial ischemia-reperfusion injury (MIRI) in mice.
Methods: A MIRI mouse model was established by left anterior descending coronary artery ligation for 45 min. According to a random number table, 66 mice were randomly divided into 6 groups (n=11 per group): the sham group, the model group, the LY-294002 group, the TXL group, the TXL+LY-294002 group and the benazepril (BNPL) group.
World J Diabetes
March 2023
Graduate School, Hebei University of Chinese Medicine, Shijiazhuang 050090, Hebei Province, China.
Background: Peripheral arterial disease (PAD) has become one of the leading causes of disa-bility and death in diabetic patients. Restoring blood supply to the hindlimbs, especially by promoting arteriogenesis, is currently the most effective strategy, in which endothelial cells play an important role. Tongxinluo (TXL) has been widely used for the treatment of cardio-cerebrovascular diseases and extended for diabetes-related vascular disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!